Shreegen Pharma Profile
Key Indicators
- Authorised Capital ₹ 25.00 Cr
as on 17-12-2024
- Paid Up Capital ₹ 25.00 Cr
as on 17-12-2024
- Company Age 12 Year, 2 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 11.69 Cr
as on 17-12-2024
- Revenue -52.92%
(FY 2021)
- Profit -6104.85%
(FY 2021)
- Ebitda -197.75%
(FY 2021)
- Net Worth -62.59%
(FY 2021)
- Total Assets -6.91%
(FY 2021)
About Shreegen Pharma
The Corporate was formerly known as Shree Gen Pharma Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 25.00 Cr and a paid-up capital of Rs 25.00 Cr.
The company currently has active open charges totaling ₹11.69 Cr.
The Key Managerial Personnel (KMP) at Shreegen Pharma Limited India is Venkata Chilukuri as CFO. Srinivasa Daka, Kanaka Reddy, Ramakrishnan Sishtla, and One other member serve as directors at the Company.
- CIN/LLPIN
U24233TG2012PLC083695
- Company No.
083695
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
18 Oct 2012
- Date of AGM
29 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Shreegen Pharma?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Chilukuri  | CFO | 01-Sep-2016 | Current |
| Rama Bobbiti | Managing Director | 18-Oct-2012 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ramakrishnan Sishtla | Director | 04-Dec-2017 | Current |
| Srinivasa Daka | Director | 18-Oct-2012 | Current |
| Kanaka Reddy | Director | 30-Sep-2016 | Current |
Financial Performance of Shreegen Pharma.
Shreegen Pharma Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 52.92% decrease. The company also saw a substantial fall in profitability, with a 6104.85% decrease in profit. The company's net worth observed a substantial decline by a decrease of 62.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shreegen Pharma?
In 2020, Shreegen Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Syngreen Lifesciences Private LimitedActive 3 years 5 months
Ramakrishnan Sishtla and Rama Bobbiti are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 13 Apr 2015 | ₹11.69 Cr | Open |
How Many Employees Work at Shreegen Pharma?
Shreegen Pharma has a workforce of 26 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shreegen Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shreegen Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
